PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC
Durvalumab consolidation provided similar benefit in EGFR M+ patients with PD-L1 ≥50% compared with EGFR M- patients. A therapeutic role of durvalumab in patients with EGFR M+, high PD-L1 unresectable stage III NSCLC should be considered.
Authors
- Sun Hyo Park
- Hee Yun Seol (ORCID: https://orcid.org/0000-0003-1840-150X)
- Shin Yup Lee (ORCID: https://orcid.org/0000-0002-2121-7335)
- Seung Soo Yoo (ORCID: https://orcid.org/0000-0002-7309-9254)
- Ji Eun Park
- J. Kim
- Yong Shik Kwon (ORCID: https://orcid.org/0000-0002-8003-7668)
- Jung Seop Eom (ORCID: https://orcid.org/0000-0002-0832-1314)
- Tae‐Hoon Kim (ORCID: https://orcid.org/0000-0003-4200-3456)
- Mi‐Hyun Kim (ORCID: https://orcid.org/0000-0002-6527-6804)
- Insu Kim (ORCID: https://orcid.org/0000-0001-8986-5016)
- Chi Young Jung
- J.C. Park
- Keum-Ju Choi
- Sun Ha Choi
- June Hong Ahn
- Jong Geol Jang
- Kyung Soo Hong
- S Kim
- Kyeong‐Cheol Shin
Institutions
- Inje University (KR)
- Changwon National University (KR)
- Gyeongsang National University (KR)
- Kyungpook National University (KR)
- Daegu Catholic University (KR)
- Pusan National University Hospital (KR)
- Dong-A University (KR)
- Keimyung University (KR)
- Yeungnam University (KR)
- Kosin University (KR)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-09-30
- DOI
- https://doi.org/10.21873/anticanres.17279
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00